About

Built for patients, not pharma.

Dose & Thrive is an independent tool for people on GLP-1 medications. No pharma funding, no conflicts of interest — just science-based tools that help you understand your own treatment.

Why this exists

GLP-1 medications are complex. They have multi-day half-lives, multi-week titration schedules, and outcomes that vary widely between people. Yet most patients are left to navigate this with a once-yearly appointment and a package insert.

Dose & Thrive gives you the same pharmacokinetic tools used in clinical research — presented in plain English. Know where your drug level is today. Know what to do if you miss a dose. Know how your progress compares to clinical trial benchmarks.

The science behind the calculator

Drug level estimates use the Bateman equation — a standard pharmacokinetic model that describes drug absorption and elimination over time:

C(t) ∝ e−ke·t − e−ka·t

ke = elimination rate · ka = absorption rate · t = time since dose

For each drug, we use the half-life and time to peak concentration (Tmax) from published prescribing information to compute ke and ka. When you have multiple logged doses, we sum contributions from each dose using pharmacokinetic superposition — the same method used in clinical PK modeling.

Results are shown as a percentage of peak concentration — not absolute ng/mL values, which vary by dose and individual — so they're meaningful regardless of your dose or body weight.

Where the benchmark data comes from

Weight loss benchmarks are derived from the landmark GLP-1 clinical trials. We interpolate between published data points to estimate expected outcomes at any week of treatment.

STEP 1 trial (Semaglutide)

Wilding et al. 2021, NEJM — Wegovy 2.4mg, n=1,306 participants

SURMOUNT-1 trial (Tirzepatide)

Jastreboff et al. 2022, NEJM — Zepbound 15mg, n=2,539 participants

Ozempic / Wegovy prescribing information

Novo Nordisk — semaglutide SC pharmacokinetics: half-life ~7 days, Tmax ~1.5 days

Mounjaro / Zepbound prescribing information

Eli Lilly — tirzepatide pharmacokinetics: half-life ~5 days, Tmax ~24 hours

What Dose & Thrive is — and isn't

An educational tool based on published science

Independent — no pharmaceutical company funding or affiliation

A way to track your personal progress over time

Medical advice — always consult your healthcare provider

A substitute for your prescriber's guidance on dosing

Affiliated with Novo Nordisk, Eli Lilly, or any drug manufacturer